Back to results
US 2020/0399706 A1Published application
Immune Gene Signatures in Cancer
AssigneeH. Lee Moffitt Cancer Center and Research Institute, Inc.
InventorsJames J. Mulé, Domenico Coppola, Timothy J. Yeatman, Audrey Loboda, Michael V. Nebozhyn
Life of this patent
Estimating the term…
Abstract
This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.
Claims9
A method of treating a subject who has a solid tumor, the method comprising:
- obtaining cells from the tumor;
- determining gene expression levels of chemokine (C-C motif) ligand 2 (CCL2), CCL3, CCL4, CCL5, CCL8, chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) (CCL18), CCL19, CCL21, chemokine (C-X-C motif) ligand 9 (CXCL9), CXCL10, CXCL11, and CXCL13 in the tumor cells;
- comparing the tumor gene expression levels to reference gene expression levels;
- identifying a subject who has tumor gene expression levels above the reference gene expression levels;
- and administering an immunotherapy treatment for cancer to a subject who has tumor gene expression levels above the reference gene expression levels.
2 more elements
Dependencies are inferred from the claim text.